CAMX.ST लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 20:59):

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...

Stats
आज की मात्रा	71 533.00
औसत मात्रा	91 128.00
बाजार मूल्य	32.33B
EPS	SEK0 ( 2024-05-07 )
अगली कमाई की तारीख	( SEK1.260 ) 2024-07-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	71.92
ATR14	SEK1.217 (0.22%)

मात्रा सहसंबंध

लंबा: 0.47 (neutral)

छोटा: 0.75 (moderate)

Signal:(62.383) Neutral

Camurus AB (publ) सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Camurus AB (publ) सहसंबंध - मुद्रा/वस्त्र

0.89
( strong )

0.92
( very strong )

0.94
( very strong )

-0.25
( neutral )

-0.82
( strong negative )

Camurus AB (publ) वित्तीय

Annual	2023
राजस्व:	SEK1.72B
सकल लाभ:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2023
राजस्व:	SEK1.72B
सकल लाभ:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2022
राजस्व:	SEK956.34M
सकल लाभ:	SEK853.08M (89.20 %)
EPS:	SEK1.010

FY	2021
राजस्व:	SEK600.57M
सकल लाभ:	SEK515.22M (85.79 %)
EPS:	SEK-1.660

Financial Reports:

No articles found.

Camurus AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.